The Hau Giang Pharmaceutical Joint Stock Company (DHG) is expected to attain post-tax profit of VND705 billion (US$31 million) in 2018, up 10 per cent year-on-year, Bao Viet Securities Company (BVSC) forecasts. According to BVSC, profits generated from the sales of non-betalactam products and supplement foods (Naturenz, Nattoenzym, Spivital) are expected to maintain its growth momentum, while that of the analgesic, antipyretic products (Hapacol) and antibiotics, betalactam products are forecast to decrease.
DHG, one of the leading companies in the pharmaceutical cosmetics industry, is expected to boost sales of new product thanks to its extensive distribution network and increasing customers’ demand for supplement products.